The company’s financial performance reflects a transition toward a dual-engine model that balances immediate service revenue with long-term asset monetization. While the group recorded a net loss of RMB224.9 million—largely attributed to a 66% surge in R&D investment—its cash reserves remain robust at RMB8.67 billion as of June 30, 2026. This capital is being funneled into autonomous laboratory systems, agent-based orchestration, and the expansion of its proprietary pipeline.
Business growth remains centered on the integration of digital AI models with physical robotic execution. Revenue from AI4S Intelligent Solutions jumped 136.4% to RMB193.5 million, bolstered by the deployment of automated workstations for global pharmaceutical partners, including Eli Lilly and JW Pharmaceutical. Simultaneously, the company is diversifying into advanced materials, notably establishing a joint venture with a JinkoSolar subsidiary to develop intelligent manufacturing lines for tandem solar cells.
The firm also launched XtalPi Science, an open infrastructure platform designed to standardize its internal R&D capabilities. By utilizing its Genius Agent suite, the company aims to move beyond traditional research tools toward autonomous discovery. With three pipelines currently in clinical stages and plans to reach approximately 20 preclinical candidates by 2027, management is positioning the platform as a foundational utility for global scientific innovation.
Comments (0)
No comments yet. Be the first!